CCA
BCYC

Catalyst Capital Advisors’s Bicycle Therapeutics BCYC Stock Holding History

Catalyst Capital Advisors’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-460
Closed -$5K – 431
2019
Q2 		$5K Buy
+460
New +$5.54K ﹤0.01% 387

Other funds holding BCYC

TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $122M AUM 26.28% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Catalyst Capital Advisors's BCYC Position: Q3 2019 in Review

Catalyst Capital Advisors sold out of Bicycle Therapeutics (BCYC) in Q3 2019, closing a stake of 460 shares — an estimated $5K sold.

Catalyst Capital Advisors first reported a position in BCYC in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 11 funds tracked by Wall St. Rank hold BCYC as of Q3 2019.

  • Catalyst Capital Advisors reported no remaining Bicycle Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 460 Bicycle Therapeutics shares in Q3 2019, an estimated $5K.
  • Catalyst Capital Advisors first reported a position in Bicycle Therapeutics in Q2 2019 and held it in 1 quarter.
  • Catalyst Capital Advisors's Bicycle Therapeutics position peaked at $5K in Q2 2019.
  • 11 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q3 2019.

Based on Catalyst Capital Advisors's 13F filing for Q3 2019, filed 5 Nov 2019.